Anti-Human Neuregulin 1-β1 - 25 µg

Quality Tested by Leinco Western Blotting: To detect Human NRG1-β1 this polyclonal antibody can be used at a concentration of 0.1-0.2 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as PN:G505 and a chromogenic substrate such as PN:T343. The detection limit for Human NRG1-β1 is 2 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:N188.

NRG1-beta 1

Next Day Ambient

Neuregulin/Heregulin is a family of related growth factors that are differentially spliced variants of four genes: NRG1, NRG2, NRG3 and NRG4. The longest forms of NRG contains several different modular domains and tissue-specific splicing results in many NRG isoforms containing different sets of these domains. Alternative splicing produces two types of EGF domain, designated a and b. HRG-Beta1 contains an Ig domain and an EGF domain necessary for direct binding to receptor tyrosine kinases erbB-3 and erbB-4. HRG-Beta1 binding causes erbB-3 and erbB-4 to dimerize with erbB-2 (Her2/neu) and thereby regulates the phosphorylation of erbB-2 tyrosines. HRG-Beta1 stimulates proliferation and motility of breast cancer cells and plays a role in wound healing by stimulating epidermal migration and differentiation of epidermal cells and by stimulating the expression of integrins in the epidermis.

NRG1-beta 1

AB_2831428

< 0.1 EU/µg as determined by the LAL method

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.